Como tratar corretamente a candidíase vulvovaginal recorrente?

Vídeo informativo sobre o panorama atual e a carga da candidíase vulvovaginal recorrente, bem como as abordagens de tratamento.

Referências: 
•    Yano J, Sobel JD, Nyirjesy P, et al. Current patient perspectives of vulvovaginal candidiasis: incidence, symptoms, management and post-treatment outcomes. BMC Womens Health. 2019;19(1):48. 
•    Denning DW, Kneale M, Rautemaa-Richardson R, Sobel JD. Global prevalence of recurrent and chronic vulvovaginal candidiasis. ESCMID, 2018. [on line] Available at: https://www.escmid.org/escmid_publications/escmid_elibrary/material/?mid... 
•    Aballéa S, Guelfucci F, Wagner J, et al. Subjective health status and health-related quality of life among women with Recurrent Vulvovaginal Candidosis (RVVC) in Europe and the USA. Health Qual Life Outcomes. 2013;11:169. 
•    Lírio J, Giraldo PC, Amaral RL, et al. Antifungal (oral and vaginal) therapy for recurrent vulvovaginal candidiasis: a systematic review protocol. BMJ Open. 2019;9(5):e027489. 
•    Tiran-Saucedo J, Garza H, Leon Y, Godinez-Burgos JA. The Search for Vaginal Candida Resistant Infections, A Descriptive Study [15R]. American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting. 2019; 133 (suppl 5):195s. 
•    Sheary B, Dayan L. Recurrent vulvovaginal candidiasis. Aust Fam Physician. 2005;34(3):147-150. 
•    Belayneh M, Sehn E, Korownyk C. Recurrent vulvovaginal candidiasis. Canadian Family Physician. 2017; 63: 455. 
•    CDC. Fungal Diseases. Antifungal Resistance. 2018 [online] Available at: https://www.cdc.gov/fungal/antifungal-resistance.html 
 

PP-PFE-BRA-2322